单中心324例患者21种肿瘤实体的成纤维细胞激活蛋白PET与组织病理学
本文为正在进行的68Ga-FAPI PET前瞻性观察试验的中期分析,纳入2018年10月至2021年10月在本院接受68Ga-FAPI PET临床显像的324例患者,涵盖21种肿瘤实体,其中237例另行18F-FDG PET。结果显示,胰腺癌和肉瘤的原发灶及胰腺癌转移灶68Ga-FAPI SUVmax均显著高于18F-FDG,多种肿瘤实体的肿瘤/本底比值亦显著更高;61份组织病理样本中68Ga-FAPI SUVmax与总体FAP免疫组化评分呈正相关(r=0.352,P=0.005)。
要点
- 胰腺癌原发灶68Ga-FAPI SUVmax 13.2 vs 18F-FDG 6.1(P<0.001),肉瘤原发灶14.3 vs 9.4(P<0.001)。
- 胰腺癌转移灶68Ga-FAPI SUVmax 9.4 vs 18F-FDG 5.5(P<0.001)。
- 68Ga-FAPI在肉瘤局部区域病灶(52 vs 48个区域)及肉瘤(137 vs 131)和胰腺癌(65 vs 57)远处转移检出上优于18F-FDG。
核心结论
- 与18F-FDG相比,68Ga-FAPI在胰腺癌和肉瘤中显示更高的绝对摄取、更高的肿瘤/本底比值,并改善胰腺癌、肉瘤及其他肿瘤实体的肿瘤检出。
- 68Ga-FAPI是肿瘤分期的新工具,具有诊疗一体化潜力。
研究设计与样本
- 本院正在进行的68Ga-FAPI PET前瞻性观察试验的中期分析,纳入2018年10月至2021年10月接受68Ga-FAPI PET临床显像的患者。
- 共324例患者、21种不同肿瘤实体接受68Ga-FAPI显像,其中237例另行18F-FDG PET。
主要发现
- 最常见肿瘤实体为肉瘤(131/324,40%)、胰腺癌(67/324,21%)和脑原发肿瘤(22/324,7%)。
- 胰腺癌原发灶平均SUVmax 68Ga-FAPI 13.2 vs 18F-FDG 6.1(P<0.001),肉瘤原发灶14.3 vs 9.4(P<0.001),胰腺癌转移灶平均SUVmax 9.4 vs 5.5(P<0.001)。
- 多种肿瘤实体的平均原发灶最大肿瘤/本底比值68Ga-FAPI显著高于18F-FDG,以胰腺癌(14.7 vs 3.0,P<0.001)和肉瘤(17.3 vs 4.7,P<0.001)最突出。
- 与18F-FDG相比,68Ga-FAPI对肉瘤局部区域病灶检出更优(52 vs 48个区域),对肉瘤(137 vs 131)和胰腺癌(65 vs 57)远处转移检出更优。
- 61份组织病理样本中,68Ga-FAPI SUVmax与总体FAP免疫组化评分呈正相关(r=0.352,P=0.005)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We present an overview of our prospective fibroblast-activation protein inhibitor (FAPI) registry study across a 3-y period, with head-to-head comparison of tumor uptake in 68Ga-FAPI and 18F-FDG PET, as well as FAP immunohistochemistry. Methods: This is an interim analysis of the ongoing 68Ga-FAPI PET prospective observational trial at our department. Patients who underwent clinical imaging with 68Ga-FAPI PET between October 2018 and October 2021 were included. Tracer uptake was quantified by SUVmax for tumor lesions and by SUVmean for normal organs. PET tumor volume (40% isocontour) and tumor-to-background ratios were calculated. Correlation between SUVmax and FAP staining in tissue samples was analyzed. Results: In total, 324 patients with 21 different tumor entities underwent 68Ga-FAPI imaging; 237 patients additionally received 18F-FDG PET. The most common tumor entities were sarcoma (131/324, 40%), pancreatic cancer (67/324, 21%), and primary tumors of the brain (22/324, 7%). The mean primary tumor SUVmax was significantly higher for 68Ga-FAPI than 18F-FDG among pancreatic cancer (13.2 vs. 6.1, P < 0.001) and sarcoma (14.3 vs. 9.4, P < 0.001), and the same was true for mean SUVmax in metastatic lesions of pancreatic cancer (9.4 vs. 5.5, P < 0.001). Mean primary tumor maximum tumor-to-background ratio was significantly higher for 68Ga-FAPI than 18F-FDG across several tumor entities, most prominently pancreatic cancer (14.7 vs. 3.0, P < 0.001) and sarcoma (17.3 vs. 4.7, P < 0.001). Compared with 18F-FDG, 68Ga-FAPI showed superior detection for locoregional disease in sarcoma (52 vs. 48 total regions detected) and for distant metastatic disease in both sarcoma (137 vs. 131) and pancreatic cancer (65 vs. 57), respectively. Among 61 histopathology samples, there was a positive correlation between 68Ga-FAPI SUVmax and overall FAP immunohistochemistry score (r = 0.352, P = 0.005). Conclusion: 68Ga-FAPI demonstrates higher absolute uptake in pancreatic cancer and sarcoma, as well as higher tumor-to-background uptake along with improved tumor detection for pancreatic cancer, sarcoma, and other tumor entities when compared with 18F-FDG. 68Ga-FAPI is a new tool for tumor staging with theranostic potential.
引用
- Hirmas N, Hamacher R, Sraieb M, et al. Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities. J Nucl Med. 2022. PMID: 36581374. doi:10.2967/jnumed.122.264689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。